Imnovid (Pomalidomide)

Imnovid (pomalidomide) is used in the management of hematologic malignancies, specifically multiple myeloma.

• Relapsed or refractory multiple myeloma: improves progression‑free survival and overall response when combined with dexamethasone in patients who have received at least two prior therapies.
• Multiple myeloma after lenalidomide failure: provides an additional therapeutic option for patients whose disease has progressed on lenalidomide‑based regimens.
• Multiple myeloma with prior proteasome inhibitor exposure: offers benefit in patients previously treated with bortezomib or carfilzomib.

• Pomalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This results in anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects, including inhibition of myeloma cell proliferation and enhancement of natural killer and T‑cell mediated cytotoxicity.

Common Side Effects

• Fatigue: persistent tiredness reported by many patients.
• Neutropenia: reduced neutrophil counts increasing infection risk.
• Gastrointestinal disturbances: nausea, constipation or diarrhea.
• Rash: mild skin eruptions.
• Anemia: lowered red blood cell levels.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia or leukopenia: may lead to serious infections.
• Secondary primary malignancies: rare occurrence of new cancers.
• Hepatic failure: elevated liver enzymes or liver dysfunction.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient history and monitor laboratory parameters.

• Pregnancy: contraindicated (Category X) – avoid use in pregnant women.
• Thrombosis risk: assess and consider prophylactic anticoagulation where appropriate.
• Hematologic monitoring: perform regular complete blood counts to detect neutropenia or anemia.
• Renal impairment: adjust dosing or monitor closely in severe renal dysfunction.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep below 25 °C, retain in the original container, protect from moisture and light.

Pomalidomide may interact with several drug classes; careful review is required.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce pomalidomide exposure.
• Anticoagulants (e.g., warfarin): increased risk of bleeding.
• Immunosuppressants (e.g., cyclosporine): may heighten toxicity.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): can increase pomalidomide plasma levels.
• Live vaccines: reduced efficacy; avoid concurrent administration.
• Hormonal contraceptives: potential decrease in effectiveness; consider additional non‑hormonal methods.